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Abstract
Many fibroblast-secreted proteins promote tumorigenicity, and several factors secreted by cancer cells have in turn been
proposed to induce these proteins. It is not clear whether there are single dominant pathways underlying these interactions
or whether they involve multiple pathways acting in parallel. Here, we identified 42 fibroblast-secreted factors induced by
breast cancer cells using comparative genomic analysis. To determine what fraction was active in promoting tumorigenicity,
we chose five representative fibroblast-secreted factors for in vivo analysis. We found that the majority (three out of five)
played equally major roles in promoting tumorigenicity, and intriguingly, each one had distinct effects on the tumor
microenvironment. Specifically, fibroblast-secreted amphiregulin promoted breast cancer cell survival, whereas the
chemokine CCL7 stimulated tumor cell proliferation while CCL2 promoted innate immune cell infiltration and angiogenesis.
The other two factors tested had minor (CCL8) or minimally (STC1) significant effects on the ability of fibroblasts to promote
tumor growth. The importance of parallel interactions between fibroblasts and cancer cells was tested by simultaneously
targeting fibroblast-secreted amphiregulin and the CCL7 receptor on cancer cells, and this was significantly more efficacious
than blocking either pathway alone. We further explored the concept of parallel interactions by testing the extent to which
induction of critical fibroblast-secreted proteins could be achieved by single, previously identified, factors produced by
breast cancer cells. We found that although single factors could induce a subset of genes, even combinations of factors
failed to induce the full repertoire of functionally important fibroblast-secreted proteins. Together, these results delineate a
complex network of tumor-fibroblast interactions that act in parallel to promote tumorigenicity and suggest that effective
anti-stromal therapeutic strategies will need to be multi-targeted.
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Introduction
Solid tumors are aberrant tissues where stromal cell types co-
develop with and influence cancer cells [1]. Significant epigenetic
alterations and gene expression changes occur in stromal cells as
tumors progress, and the stromal changes are as strikingly
different as those observed in the cancer epithelial compartments
[2–5]. Many of these stromal cell changes are elicited by factors
secreted by cancer cells, such as vascular endothelial growth
factor (VEGF; MIM: 192240), which helps recruit and induce
proliferation of endothelial cells [6]. Cancer cells also secrete
factors that alter surrounding fibroblasts, such as transforming
growth factor (TGF)-b (MIM: 190180) which induces fibroblasts
to differentiate into myofibroblasts and secrete collagen, thereby
contributing to the abundant extracellular matrix often observed
in epithelial tumors [7]. In addition to TGF-b factors secreted by
cancer cells that influence stromal fibroblasts include platelet
derived growth factor (PDGF; MIM: 173430), interleukin (IL)-6
(MIM:147620), IL1-a (MIM: 147760), and WNT1 inducible
signaling pathway protein (WISP)-1 and -2 (MIM: 603398 and
603399) [8,9].
Tumor associated fibroblasts have been shown to promote
cancer cell proliferation, angiogenesis, extracellular matrix (ECM)
remodeling, inflammation, invasion and metastasis [10,11].
Several fibroblast-secreted or membrane-bound factors that
mediate these effects have been identified, including CXCL12
(MIM: 600835), hepatocyte growth factor (HGF; MIM:142409),
matrix metalloproteinase MMP14 (MIM: 600754), osteopontin
(MIM: 166490), TGF-b, and CCL2 (MIM: 158105) [12–17].
Some basic underlying processes involved in regulating the
interactions between the epithelial cancer cells and the stromal
fibroblasts have been identified. For example, several fibroblast-
secreted factors are inflammatory cytokines whose expression is
driven by NF-kappaB-dependent transcription in a process similar
to the senescent secretory phenotype observed in aging fibroblasts
[18,19]. Additionally, a study of how fibroblasts co-evolve with
tumor cells determined that fibroblasts gradually implement two
signaling loops, involving TGF-b and CXCL12, which act together
through both autocrine and cross-signaling mechanisms [20].
What remains unclear is whether the different factors involved in
cancer cell-fibroblast interactions reflects a requirement of a
multitude of fibroblast factors acting in parallel to promote
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tumorigenicity, or whether it reflects the diversity of the
approaches and systems used to identity important interactions.
Here, we designed a study to explore how the entire repertoire of
fibroblast-secreted factors that are induced by human cancer cells
function as a whole and compared the factors. This systems-level
study was designed to be complimentary to approaches that focus
on single genes or single processes. Our study indicates that the
majority of induced fibroblast-secreted factors play a role in
promoting tumorigenicity and that they do so through diverse
effects on the tumor tissue.
Results
Comparative genomic analysis of pro-tumorigenic
fibroblast factors induced by breast cancer cells
We adapted previously used systems of human cancer cells and
fibroblasts [21–23], by using fibroblast lines that were amenable
for the use of stable RNA interference (shRNA) so the relevance of
candidate mediators of tumor-stromal interactions could be tested.
We determined using co-injection assays that two human
fibroblast lines previously shown to promote tumorigenicity in
other systems (HFFF2 and HFF1) were able to promote
tumorigenicity of two basal breast cancer subtype cell lines,
MDA-MB-231 and Cal51, whereas two other human fibroblast
lines (Wi-38 and CCD1112Sk) were not (Figure S1). We used the
two tumor-supportive fibroblast lines (HFFF2 and HFF1) as
models for patient-derived breast carcinoma associated fibroblasts
and the two non-supportive fibroblasts as models for normal breast
tissue derived fibroblasts. Using fibroblasts cell lines allowed
shRNA transfection, selection and subsequent validation of gene
silencing, whereas patient-derived breast fibroblasts cannot be
passaged in culture long enough for such manipulations (data not
shown; Ahmet Acar, personal communication). To determine at
which point the host murine fibroblasts replaced the co-injected
human fibroblasts, we tagged the human fibroblasts with green
fluorescent protein (GFP) so that we could visualize how long they
survived ensconced within developing tumors. We found that after
three weeks, the number of co-injected GFP-tagged human
fibroblasts comprised roughly 20% of the tumor stroma as judged
by co-localization of GFP and the fibroblast stromal marker alpha-
smooth muscle actin (a-SMA) (Figure S2), but the relative
contribution steadily declined from week 3 to week 8, although
the GFP-fibroblasts never completely disappear. The level of a-
SMA positive cells within tumor stroma persisted during this same
time period (Figure S2).
We performed transcriptional profiling and pathway analysis to
determine if exposure of our model tumor-supportive fibroblasts
to breast cancer cells in co-culture resembled expression changes
seen in patient-derived breast carcinoma fibroblasts. We com-
pared expression profiles of HFF1 and HFFF2 tumor-supportive
fibroblasts co-cultured with either Cal51 or MDA-MB-231 (four
combinations total) to those of Wi-38 and CCD1112Sk non-
supportive fibroblasts co-cultured with either Cal51 or MDA-
MB-231 (another four combinations). We chose to work with
basal subtype breast cancer cell lines due to the greater need to
develop new treatments for this poor prognosis subtype. We then
compared the pathways selectively enriched in tumor-supportive
fibroblasts co-cultured with Cal51 and MDA-MB-231 to path-
ways enriched by comparing cultures of patient-derived breast
carcinoma fibroblasts to their normal counterparts. Strikingly, the
top four pathways identified by gene-set enrichment analysis
(GSEA) that are activated by exposure of tumor-promoting
human fibroblasts to breast cancer cells are also amongst the top
ten pathways activated in cultures of patient-derived breast
carcinoma fibroblasts relative to normal fibroblasts (Figure 1).
These pathways are ECM-receptor interaction, focal adhesion,
integrin signaling and integrin cell-surface interactions; interre-
lated pathways that have been shown to be involved in the
activation of cancer associated fibroblasts [21,24,25]. Addition-
ally, most of the other top ten activated pathways in both systems
were activated in the other system at lower ranking but still
significant levels. These pathways included cytokine cytokine-
receptor interactions, PDGF signaling, and Rho GTPase signal-
ing; which likewise have shown to be involved in activation of
cancer associated fibroblasts [7,13,26] (Figure 1). On the whole,
the overlap in all significantly activated pathways is 44% (Table
S1). This affirmed that this system of tumor-promoting human
fibroblasts resembled in vitro cultures of patient-derived breast
cancer fibroblasts.
We next wanted to test whether this system also reflected
changes observed in vivo in human primary breast cancer stroma.
To address this, we used gene-set enrichment analysis to
determine the pathways that were activated in microdissected
human breast stroma relative to normal breast stroma [3].
Despite the fact that human breast stroma contains many cell
types in addition to fibroblasts, four of the eight significantly
activated pathways in human breast stroma were also signifi-
cantly activated by exposure of tumor-promoting fibroblasts to
breast cancer cells, including cytokine/cytokine-receptor interac-
tions and JAK-STAT signaling (Figure 1). Additionally, we
developed a gene signature based on stimulation of tumor-
promoting fibroblasts by breast cancer cells. Based on both
clustering and principal component analysis, this gene signature
was able to correctly predict whether microdissected human
breast stroma was derived from cancerous or normal breast tissue
for 98 of 99 samples (Figure 1). These comparative genomic
analyses establish the close correspondence of our system of
interaction of breast cancer cells with tumor-promoting fibro-
blasts to stroma and stromal fibroblasts isolated from primary
human breast cancer.
Author Summary
There is increasing interest in developing methods to treat
cancer by targeting non-cancer cells that play supportive
roles in the tumor microenvironment. One type of non-
cancer cell that has received considerable attention along
these lines is cancer-associated fibroblasts, which can
promote tumor formation and tumor growth. There have
been several studies showing that inhibition of individual
fibroblast genes or proteins dramatically reduces the
tumor supportive function of fibroblasts. From the
perspective of developing a therapeutic strategy, what
remains unclear is whether the several different important
factors discovered to date reflect the requirement of a
multitude of fibroblast factors to promote tumorigenicity,
or whether it reflects the diversity of the epithelial cancer
cells and fibroblasts used in these different studies. Here,
we addressed this question directly using a single system
of fibroblasts and breast cancer epithelial cells. Important-
ly, we found that a multitude of fibroblast factors are
indeed required to promote tumorigenicity, and that they
have different effects on the tumor microenvironment.
Furthermore, we found that inhibiting multiple fibroblast-
secreted factors is more efficacious than blocking individ-
ual factors. These results suggest that fibroblasts and
cancer cells act through multiple parallel pathways and
that effective anti-stromal therapeutic strategies will need
to be multi-targeted.
Complex Network of Tumor-Fibroblast Interactions
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Figure 1. Comparative genomic analysis of expression changes induced by breast cancer cells in tumor-supportive fibroblasts,
patient-derived carcinoma-associated fibroblasts, and microdissected breast stroma. (A) Top ten pathways identified by GSEA analysis of
exposure of tumor-supportive fibroblasts to breast cancer cells; blue indicates overlap with the top ten pathways activated in patient-derived breast
cancer fibroblasts; green indicates overlap with other pathways significantly activated in patient-derived breast cancer fibroblasts; grey indicates no
overlap, (B) Top ten pathways identified by GSEA analysis of patient-derived breast cancer fibroblasts relative to their normal counterparts; blue
indicates overlap with the top ten pathways activated by exposure of tumor-supportive fibroblasts to breast cancer cells; green indicates overlap with
other pathways significantly activated by exposure of tumor-supportive fibroblasts to breast cancer cells; grey indicates no overlap, (C) Top ten
pathways identified by GSEA analysis of microdissected breast cancer stroma relative to normal breast stroma, green indicates overlap with pathways
significantly activated by exposure of tumor-supportive fibroblasts to breast cancer cells, but not in the top ten; grey indicates no overlap. (D) A
tumor-supportive fibroblast gene signature was used in unsupervised clustering to classify normal (green) and tumor (red) microdissected breast
stroma samples. (E) The same signature was used in principal component analysis to observe the separation of normal (green) and tumor (red)
microdissected breast stroma samples.
doi:10.1371/journal.pgen.1003789.g001
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Table 1. 42 secreted proteins selectively induced by breast cancer cells in tumor-promoting fibroblasts.
Gene











CCL8 602283 chemokine (C-C motif) ligand 8 Cytokine Inflammatory No 21217759
TNFSF15 604052 tumor necrosis factor superfamily, member 15 Cytokine Suppressive No 22833050
CCL2 158105 chemokine (C-C motif) ligand 2 Cytokine Oncogenic Yes 22472119
CCL20 601960 chemokine (C-C motif) ligand 20 Cytokine Oncogenic Yes 21847358
CCL5 187011 chemokine (C-C motif) ligand 5 Cytokine Oncogenic Yes 21252118
CCL7 158106 chemokine (C-C motif) ligand 7 Cytokine Oncogenic Yes 19937793
CSF3 138970 colony stimulating factor 3 (granulocyte) Cytokine Oncogenic No 12492491
CXCL10 147310 chemokine (C-X-C motif) ligand 10 Cytokine Oncogenic No 17409450
CXCL5 600324 chemokine (C-X-C motif) ligand 5 Cytokine Oncogenic Yes 19047182
FST 136470 Follistatin Other Oncogenic Yes 19740438
IL11 147681 interleukin 11 Cytokine Oncogenic No 12842083
IL1A 147760 interleukin 1, alpha Cytokine Oncogenic No 9618523
IL1B 147720 interleukin 1, beta Cytokine Oncogenic Yes 20138012
IL1RN 147679 interleukin 1 receptor antagonist Cytokine Suppressive No 21519029
IL24 604136 interleukin 24 Cytokine Suppressive No 20926331
IL8 146930 interleukin 8 Cytokine Oncogenic Yes 22422937
COL7A1 120120 collagen, type VII, alpha 1 ECM Suppressive Yes 22564523
SPON1 604989 spondin 1, extracellular matrix protein ECM Oncogenic No 19549008
TNFAIP6 600410 tumor necrosis factor, alpha-induced protein 6 ECM Anti-inflammatory No 9244409
DPT 125597 Dermatopontin ECM Oncogenic No 16899568
POSTN 608777 periostin, osteoblast specific factor ECM Oncogenic Yes 22158103
VCAN 118661 Versican ECM Oncogenic Yes 19160015
SPP1 166490 secreted phosphoprotein 1 ECM Oncogenic No 21252118
AREG 104640 Amphiregulin Growth factor Oncogenic No 18470483
EGFL6 300239 EGF-like-domain, multiple 6 Growth factor None known No
STC1 601185 stanniocalcin 1 Growth factor Oncogenic No 20484106
UCN2 605902 urocortin 2 Growth factor Suppressive No 18308934
NRG1 142445 neuregulin 1 Growth factor Oncogenic Yes 22535374
WISP1 603398 WNT1 inducible signaling pathway protein 1 Growth factor Suppressive Yes 21516124
C3 120700 complement component 3 Other HSPC recruitment No 16863905
FAM20C 611061 family with sequence similarity 20, member C Other None known No
FJX1 612206 four jointed box 1 (Drosophila) Other None known No
IGFBP5 146734 insulin-like growth factor binding protein 5 Other Suppressive No 21460855
ISG15 147571 ISG15 ubiquitin-like modifier Other None known No
PAPPA 176385 pregnancy-associated plasma protein A, pappalysin 1 Protease Oncogenic No 21303951
PCSK1 162150 proprotein convertase subtilisin/kexin type 1 Protease Oncogenic No 20052009
SERPINB2 173390 serpin peptidase inhibitor, clade B (ovalbumin), member 2 Other Suppressive No 1427403
SPINT1 605123 serine peptidase inhibitor, Kunitz type 1 Other Suppressive No 16103220
MMP1 120353 matrix metallopeptidase 1 (interstitial collagenase) Protease Oncogenic Yes 11990853
MMP11 185261 matrix metallopeptidase 11 (stromelysin 3) Protease Both oncogenic and
suppressive
Yes 11990853
MMP12 601046 matrix metallopeptidase 12 (macrophage elastase) Protease Oncogenic No 21378275
MMP3 185250 matrix metallopeptidase 3 (stromelysin 1, progelatinase) Protease Oncogenic Yes 11990853
Results of literature searches on the 42 secreted proteins selectively induced in tumor-supportive fibroblasts. Descriptions are from Ingenuity (www.ingenuity.com).
Semi-automated searches were performed using the gene symbols and different search terms (e.g. stromal fibroblast, tumor microenvironment, cancer) with PubMatrix
(pubmatrix.grc.nia.nih.gov).
doi:10.1371/journal.pgen.1003789.t001
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Determining the repertoire of fibroblast-secreted factors
that are induced by breast cancer cells
We used genome-wide analysis to determine the full repertoire
of secreted factors induced by breast cancer cells in our tumor-
promoting fibroblasts. As the first step, we compared genes
induced in tumor-promoting fibroblast lines to genes induced in
fibroblast lines incapable of promoting tumorigenicity. We found
320 genes that were more than 2-fold greater induced in tumor-
promoting fibroblasts (Table S2) and within this group were 62
genes encoding secreted proteins. Of these, 42 were also
significantly upregulated (p,0.05) in stromal cells isolated from
primary breast cancer relative to normal breast stroma cells
[3,4,27]. This group contained cytokines (15), extracellular matrix
proteins (7), proteases (6), and growth factors and hormones (6)
(Table 1). Cytokines as a class were significantly enriched in our
screen relative to their representation in the set of all secreted
proteins (36% vs. 12%, p= 5.6e-6). This enrichment is consistent
with the prior reports that cytokines play key roles in the tumor-
supportive function of tumor-associated fibroblasts [19]. In
contrast, the other functional classes of secreted proteins were
not significantly enriched. The cytokines upregulated in tumor-
supportive fibroblasts included CC- and CXC-chemokines (CCL-
2, -5, -7, -8, -20, and CXCL-5, -10; MIM: 158105, 187011,
158106, 602283, 600324 and 147310 respectively), pro-inflam-
matory interleukins (IL-1a, -1b, -8, -11, -24; MIM: 147760,
147720, 146930, 147681 and 604136 respectively), colony
stimulating factor (G-CSF; MIM: 138970), interleukin receptor
antagonist (IL1RN; MIM: 147679), and TNF superfamily member
TNSF15 (MIM: 604052) (Table 1). Systematic literature searches
revealed that 16 of the 42 secreted proteins had one or more
publication(s) implicating them in the tumor-supportive function of
fibroblasts while 26 did not (Table 1). The genes not previously
implicated as mediators of the tumor-supportive function of
fibroblasts included the majority (8/15) of cytokines, one-half (3/6)
of the proteases, and the majority (4/6) of the growth factors and
hormones. Examples include CCL8, encoding a chemokine not
previously linked to cancer that is involved in homing of memory
T lymphocytes to inflamed skin [28]; pregnancy-associated plasma
Figure 2. Tumor-supportive fibroblasts have profound effects on the composition of the tumor microenvironment. (A) Tumor-
supportive fibroblasts HFFF2 increase Cal51 tumor cell proliferation and increase stromal components (bottom panel) as compared to tumors formed
using Cal51 alone (top panel). Immunohistochemical analysis using antibodies to Ki-67 (proliferation), antigen #7/4 (neutrophils and monocytes),
CD31 (blood vessels), and a-SMA (mesenchymal cells). Scale bars represent 50 mm for Ki-67,#7/4 and CD31 and 100 mm for a-SMA. (B) Quantification
of Ki-67 positive (proliferating) tumor cells. Five different fields of three different tumors per group were scored. Asterisk indicates a significant
difference between cell line only (Cal51shNT) and co-injection (Cal51shNT+HFFF2) groups (p,0.01). Data are expressed as the mean 6 SEM. (C–E)
Similarly performed quantification of monocytes and neutrophils, endothelial cells, and activated mesenchymal cells (p,0.01).
doi:10.1371/journal.pgen.1003789.g002
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Figure 3. shRNA silencing of CCL2, CCL7 or CCL8 in tumor-supportive fibroblasts reduces their ability to promote tumorigenicity. (A)
Reduction of CCL2 protein in HFFF2 fibroblasts by expressing shRNAs targeting CCL2 as indicated compared to non-targeting (N.T.) control
determined by immunoblotting. Beta-actin was used as a loading control. (B) Reduction of CCL7 protein levels in HFFF2 fibroblasts expressing
shRNAs targeting CCL7. (C) Reduction in CCL8 RNA levels in HFFF2 fibroblasts expressing shRNAs targeting CCL8 compared to HFFF2 fibroblasts
expressing non-targeting (N.T.) control. Asterisk indicates a significant difference (p,0.01) between the experimental (shCCL8) and control (shN.T.)
group. (D) Tumorigenicity of Cal51 cells alone or co-injected with HFFF2 cells expressing either no shRNA, control shRNA or shRNAs targeting CCL2.
Tumor-take rate for the total injections for each group is indicated. Asterisks indicate significant differences (p,0.01) in tumor volumes for shCCL2-1
and shCCL2-2 compared to control. Hashtag indicates a significant difference (p,0.05) between cell line only (Cal51) and Cal51 co-injected with
HFFF2 fibroblasts. Error bars represent SEM. (E) Effects of shRNAs targeting CCL7 (p,0.01). There was no significant difference in the tumor volumes
between the two knockdown groups (p = 0.3, 0.3, 0.2 and 0.5 at weeks 3, 4, 5 and 6 post injections respectively). (F) Effects of shRNAs targeting CCL8
(p,0.01). (G) Tumorigenicity of MDAMB231 cells alone or co-injected with HFFF2 cells expressing either no shRNA, control shRNA or shRNAs
targeting CCL2. Tumor-take rate for the total injections for each group is indicated. Asterisks indicate significant differences in tumor volumes for
shCCL2-1 and shCCL2-2 compared to control (p,0.01). Hashtag indicates a significant difference between cell line only (MDAMB231) and MDAMB231
coinjected with HFFF2 fibroblasts (p,0.05 and n=10 per group). Errors represent SEM. (H) Effects of shRNAs targeting CCL7 (p,0.01). (I) Effects of
shRNAs targeting CCL8 (p,0.01). The lack of effects of the CCL-targeting shRNAs on fibroblast proliferation are shown in Figure S4.
doi:10.1371/journal.pgen.1003789.g003
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Figure 4. Diverse effects on the tumor microenvironment mediated by fibroblast secretion of the related chemokines CCL2, CCL7
and CCL8. (A) Immunohistochemical analysis of the effects of suppressing CCL2, CCL7 or CCL8 in tumor-supportive fibroblasts on cancer cell
proliferation, immune cell recruitment, blood vessel recruitment and mesenchymal cell activation in Cal51 tumors, using antibodies to Ki-67
(proliferation), antigen #7/4 (immune cells; neutrophils and monocytes), CD31 (endothelial cells of blood vessels) and a-SMA (mesenchymal cell
activation). Scale bars represent 50 mm for Ki-67, antigen #7/4 and CD31 panels and 100 mm for a-SMA. (B–E) Quantification of tumor cell
proliferation, monocytes and neutrophils, blood vessel endothelial cells, and mesenchymal cell activation. For each property, five different fields of
three different tumors per group were scored. Data are expressed as the mean 6 SEM. Asterisks indicates a significant difference between the
experimental shRNAs and control non-targeting shRNA (p,0.01).# indicates a significant difference in proliferation in Cal51 only group compared to
Cal51 coinjected with HFFF2 fibroblasts (p,0.01). Data are expressed as the mean 6 SEM.
doi:10.1371/journal.pgen.1003789.g004
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protein-a (PPAPA; MIM: 176385), a protease that degrades IGF-
binding proteins and acts as a positive modulator of local IGF
signaling in skin repair [29]; and EGFL6 (MIM: 300239), encoding
an epidermal growth factor (EGF) repeat protein expressed in
osteoblastic-like cells and capable of inducing migration of
endothelial cells [30].Some of the fibroblast-secreted candidate
tumor-supportive factors fall outside of the known classes of
proteins involved in tumor-stromal interactions, including ISG15
(MIM: 147571), an interferon-inducible, ubiquitin-like protein
whose secretion plays a critical role in mediating an effective
immune response to mycobacteria [31]; and complement compo-
nent C3 (MIM: 120700), which in addition to its role in the
complement cascade helps mobilize hematopoietic stem/progen-
itor cells to wounds [32].
Development of functional assays to test the effects of
selected candidate mediators of fibroblasts on tumor
growth and tumor microenvironment
In order to characterize the effects of fibroblasts on tumor
progression, we co-injected tumor-promoting fibroblasts and exam-
ined their effects on both tumor cells and associated non-tumor cells
within the tumor microenvironment. Consistent with a faster tumor
growth rate, cancer cells in the co-injected tumors exhibited a two-
fold higher proliferative rate based on Ki-67 labeling (Figure 2). To
visualize and quantify the presence of three of the most important
features of the tumor microenvironment - inflammation, vascular-
ization and fibroblast activation - we performed immunohistochem-
ical analysis at week six after co-injection. We used antibodies to the
7/4-antigen, which is highly expressed in neutrophils and inflam-
matory monocytes [33], the CD31 endothelial antigen, which
visualizes blood vessels [34], and a-SMA, which is expressed by
activated fibroblasts [35]. Strikingly, the presence of inflammatory
cells, degree of vascularization, and number of activated fibroblasts
were all 3 to 4 fold higher in the co-injected tumors (Figure 2),
indicating a profound influence of tumor-supportive fibroblasts on
the composition of the tumor microenvironment.
We decided to analyze a mix of previously implicated and novel
candidate pro-tumorigenic fibroblast-secreted factors. Additional-
ly, we wanted to test whether seemingly redundant factors were
indeed functionally redundant. We focused on cytokines, growth
factors, and hormones, and chose CCL2 and CCL7 (both
previously validated as functionally important fibroblast secreted
factors [17,36]); the related factor CCL8 which, like CCL7, binds
CCR1 (MIM: 601159); amphiregulin (AREG; MIM: 104640),
which has been implicated in tumor stromal-interactions but as a
ligand produced by cancer cells acting on fibroblasts [37]; and
stanniocalcin1 (STC1; MIM: 601185), which has been shown to
act as a cancer cell autonomous factor, but not as a stromally
produced factor [38]. For each of these five genes, we confirmed
by quantitative RT-PCR that there was a significant induction in
the co-cultured tumor supportive fibroblasts relative to the co-
cultured neutral fibroblasts (Figure S3).
CCL2, CCL7 and CCL8 chemokines mediate tumor
supportive abilities of fibroblasts with distinct effects on
the tumor microenvironment
CCL2, CCL7, and CCL8 are structurally related chemokines
that share a common function of recruitment of monocytes to
areas of injury and inflammation [39]. Based on their structural
similarity and overlapping functions in inflammation, we wanted
to determine if they had redundant roles in the tumor supportive
function of co-injected fibroblasts. Remarkably, shRNAs directed
against each of these three cytokines suppressed tumorigenicity in
the co-injection assay, with the strongest effects observed when
silencing CCL2 (53%) or CCL7 (66%) compared to weaker effects
exerted by silencing of CCL8 (25%) (two validated shRNAs per
gene, Figure 3). Interestingly, despite their related structure,
silencing of each of the three cytokines had a distinct impact on the
tumors: silencing of CCL2 suppressed recruitment of innate
immune cells and angiogenesis (Figure 4) almost to the same
levels as in tumors without co-injected fibroblasts. In contrast,
silencing of CCL8 suppressed only the recruitment of innate
immune cells, while silencing of CCL7 reduced tumor cell
proliferation almost to the levels observed in tumors growing in
the absence of co-injected fibroblasts (Figure 4 and Figure S4).
Our data therefore showed that these related chemokines had
non-redundant roles in mediating fibroblast-supportive functions.
Suppressing AREG reduces the ability of fibroblasts to
support tumorigenicity
We next tested whether silencing of AREG in fibroblasts affected
tumor supportive function. Silencing of AREG had a pronounced
effect, with an average reduction in tumor size at six weeks of 55%
to 65% (Figure 5). In contrast to the chemokines, silencing AREG
in fibroblasts had no effect on the number of blood vessels or
Figure 5. Suppressing amphiregulin expression in tumor-supportive fibroblasts reduces tumorigenicity and amount of
mesenchymal cells. (A) Reduced amphiregulin protein levels in HFFF2 fibroblasts expressing two distinct shRNAs directed against AREG
compared to cells expressing non-targeting shRNA (immunoblotting). b-actin was used as a loading control. shAREG-2 was more potent at
suppression both by immunoblotting and quantitative RT-PCR (see also Figure S3). (B) Reduced tumorigenicity of Cal51 cells co-injected with HFFF2
cells expressing either shRNAs targeting AREG as compared to control shRNA. Tumor-take rates for each group are indicated. Asterisks denote
significant differences in tumor volumes for shAREG-1 or shAREG-2 compared to control (p,0.05) Data are expressed as the mean6 SEM. (C) As with
(B) but for MDA-MB-231 breast cancer cells. p,0.05. (D) Immunohistochemical analysis of the effects of suppressing amphiregulin expression in
tumor-supportive fibroblasts HFFF2 on Cal51 tumor cell proliferation and the tumor microenvironment (bottom panel) compared to tumors formed
using Cal51 co-injected with control HFFF2 (top panel) as described in the legend to Figure 2. (E) Quantification of Ki-67 positive tumor cells in Cal51
tumors injected with control HFFF2 fibroblasts or shAREG-2 HFFF2 fibroblasts. Five different fields of three different tumors per group were scored.
Error bars represent SEM. There was a small decrease in proliferation in the shAREG-2 HFFF2 fibroblast group (not statistical significance, p = 0.06). (F)
Similarly performed quantification of monocytes and neutrophils, with a slight decrease observed in the shAREG-2 HFFF2 fibroblast group (not,
significant, p = 0.14). (G) Similarly performed quantification of blood vessel endothelial cells, with no significant difference (p = 0.24). (H) Similarly
performed quantification of activated mesenchymal cells, asterisk indicates a significant difference (p = 0.002). (I) Pericyte coverage of tumor
associated blood vessels in tumors derived from injection of Cal51 cells with HFFF2 fibroblasts expressing shRNA-targeting AREG compared to
control. Fifteen vessels from three tumors were examined for each group were analyzed for the ratio of pericytes (a-SMA+) to endothelial cells
(CD31+). Data are expressed as the mean 6 SEM. (J) The effect of amphiregulin on the replicative rate of wild-type mouse embryonic fibroblasts (WT-
MEFs) measured by quantifying BrdU incorporation. Data representative of three independent experiments are shown. Concentration of
amphiregulin (AREG ng/ml) is indicated on the x-axis. Asterisk indicates significant differences (p,0.05) between the control (0 ng/ml AREG) and
experimental groups (10, 50, 100 and 200 ng/ml AREG). (K) As in J, but assaying the replicative rate of human fibroblasts, HFFF2.
doi:10.1371/journal.pgen.1003789.g005
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Figure 6. Amphiregulin is a chemoattractant for fibroblasts and helps prevent necrosis and tumor cell death. (A) Photomicrographs of
mouse fibroblasts that have transversed a Boyden chamber in response to different concentrations of amphiregulin in the opposing chamber.
Migration was measured 5 hours post plating. Scale bars represent 100 mm. (B) Amphiregulin promotes migration of mouse embryonic fibroblasts
(MEFs) in a scratch wound-healing assay (photomicrographs at indicated time after initiation of assay). (C) Quantification of the Boyden migration
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innate immune cells (Figure 5). However, immunohistochemical
analysis of the percentage of cells within the tumor that expressed
a-SMA, a marker of mesenchymal-derived cells such as activated
fibroblasts, revealed a 78% reduction. This level was comparable
to the low levels of a-SMA positive cells in tumors formed in the
absence of co-injected fibroblasts (Figure 5). Although a-SMA is
expressed by activated pericytes, a cell type that surrounds
endothelial cells of blood vessels, we did not observe a difference
in number of a-SMA cells associated with blood vessels (Figure 5).
This suggested that secretion of amphiregulin by the co-injected
human fibroblasts plays a major role in establishing a tumor
microenvironment that is enriched for activated fibroblasts, and
since the co-injected human fibroblasts are almost entirely
replaced by mouse fibroblasts at the point of excision (6 weeks),
this effect must be propagated through recruited mouse fibroblasts.
Consistent with this, we found that amphiregulin increased
proliferation of mouse fibroblasts, as well as human fibroblasts
(Figure 5). We also found that amphiregulin was a chemoattrac-
tant for mouse fibroblasts in migration and invasion assays,
suggesting a mechanism of recruitment into the tumor, and that
amphiregulin directly activated fibroblasts as judged by induction
of a-SMA expression (Figure 6).
In addition to the pronounced reduction of activated fibroblasts
when AREG was silenced, we also noted changes in activation of
the amphiregulin receptor EGFR (MIM: 131550) on tumor cells.
Compared to tumor cells co-injected with control tumor-support-
ive fibroblasts, tumor cells when co-injected with AREG-silenced
fibroblasts showed a ,2-fold reduction of activated, phospho-
EGFR as measured by immunohistochemistry (Figures 6). This
was accompanied by a minor, barely significant (p = 0.06),
negative effect on tumor cell proliferative rate in vivo, with no
direct effect of amphiregulin on tumor cell proliferation in vitro
(Figure 5 and Figure S5). In contrast, we found a significant
increase in necrosis in tumors after silencing of fibroblast-secreted
amphiregulin (Figure 6). Notably, amphiregulin significantly
protected the breast cancer cells from cell death induced by
detachment from their normal extracellular matrix (anoikis,
Figure 6). Together, these results suggest that fibroblast-secreted
amphiregulin has potent effects on tumor progression, with
autocrine effects leading to activation of fibroblasts and paracrine
effects protecting cancer cells from cell death.
Strong tumor suppressive responses are achieved by
simultaneously targeting different mediators of tumor-
fibroblast interactions on both cell types
Co-culturing also lead to changes in gene expression in the
breast cancer cells, which upregulated a shared receptor for
CCL2 and CCL7, the chemokine receptor CCR1 upon co-
culturing with tumor-supportive fibroblasts (Figure 7). We
therefore tested whether CCR1 expression by cancer cells was
critical for some of the tumor supportive functions of fibroblasts
by stably expressing shRNAs targeting CCR1 in Cal51 breast
cancer cell line (knockdown efficiency was quantified by both
qRT-PCR and immunoblotting, Figure S6). Silencing of CCR1
had no effect on tumor growth when cancer cells were injected
alone. However, in the context of co-injection with fibroblasts,
silencing of cancer cell CCR1 resulted in a 3-fold reduction in
tumor size, almost eliminating the effect of the fibroblasts
(Figure 7 and Figure S6). We further observed a 40% reduction
in the proliferative index of cancer cells and a 2-fold reduction in
recruitment of neutrophils and inflammatory monocytes to the
tumor, but only minor effects on the number of blood vessels and
mesenchymal cells (Figure 7 and Figure S6). Thus, expression of
CCR1 by cancer cells plays a critical role in enabling fibroblasts
to exert tumor supportive function, through increased tumor cell
proliferation and potentially indirectly through recruitment of
leukocytes.
We next asked whether blocking two interactions between
fibroblasts and cancer cells was more effective than blocking either
one alone. We therefore asked whether simultaneously silencing
fibroblast-secreted amphiregulin and cancer cell expressed CCR1
was more efficacious than blocking either alone. We found that
tumor growth was significantly more reduced when both pathways
were targeted (Figure 7).
Cancer cell induction of the fibroblast-secreted proteins
requires parallel activation
A number of studies have implicated specific cancer-cell
secreted factors in the activation of neighboring fibroblasts,
including TGF-b [40] and IL-1b [19]. We wanted to determine
whether the repertoire of tumor-promoting fibroblast secreted
factors could be induced by single specific inducers, or whether
multiple pathways were acting in parallel. To test this, we used
quantitative RT-PCR to measure gene expression changes in
tumor-promoting fibroblasts of the five factors (CCL-2, -7, -8,
AREG, and STC1) that we had determined all had functional
relevance, along with two others factors (NRG1; MIM: 142445 and
WISP1) that also were induced in the system. Surprisingly, TGF-b,
did not induce expression of any of the seven factors (Table 2),
despite its ability to induce activation of fibroblasts to myofibro-
blasts, which resembles many aspects of carcinoma-associated
fibroblasts [10]. AREG also did not induce expression of any of the
seven factors, despite its key role in stimulating mammary
fibroblasts during normal mammary development [37]. IL-1b, a
potent activator of NF-kB signaling, produced an upregulation in
assay. Data are expressed as the mean 6 SEM. Asterisks indicate a significant difference (p,0.05) between experimental and control groups. (D)
Quantification of migration in scratch wound healing assay (cells that had moved into the scratched area as percent of control). Asterisk indicates a
significant difference between the control and experimental group (p,0.05). (E) Quantitative RT-PCR analysis of a-SMA expression (relative to
GAPDH) in HFFF2 fibroblasts (gray bars) and Wi38 fibroblasts (red bars) upon treatment with amphiregulin. Asterisk indicates a significant difference
between untreated HFFF2 fibroblasts and those treated at 50 and 100 ng/ml (p value 0.01 and 0.001, respectively). All data are expressed as the mean
6 SEM. (F) Necrosis in Cal51+HFFF2 tumors with control shRNA or with shRNA targeting AREG as visualized by H&E staining. Dashed lines indicate
necrotic areas. Scale bars represent 1 mm. (G) Quantification of necrosis in Cal51+HFFF2 tumors with control shRNA or with shRNA targeting AREG.
Necrotic area was calculated from five different tumors per group. Data are expressed as the mean 6 SEM. Asterisks indicate a significant difference
(p = 3e-4) between experimental and control groups. (H) EGFR activation (phosphorylation) in Cal51+HFFF2 tumors with control shRNA or with shRNA
targeting AREG detected by immunostaining using an antibody to phospho-EGFR (Tyr1068). Scale bars represent 50 mm. (I) Quantification of
phospho-EGFR positive tumor cells in Cal51+HFFF2 tumors with control shRNA or with shRNA targeting AREG. Areas positive for pEGFR were
calculated from five different fields of five different tumors per group. Asterisk indicates that the experimental group is significantly different than the
control (p = 0.007). Data are expressed as the mean6 SEM. (J) Effects of amphiregulin on the viability of Cal51 cells plated on non-adhesive plates and
cultured for 24 hours (anoikis assay). Viability was determined by measuring calcein AM uptake. Asterisk indicates that the experimental group is
significantly different than the control (p,0.05). Data are expressed as the percentage of viable cells normalized to control with the error bars
representing SEM.
doi:10.1371/journal.pgen.1003789.g006
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Figure 7. Combined inhibition of chemokine and amphiregulin signaling is more effective at blocking the effects of tumor
supportive fibroblasts. (A) Paracrine upregulation of the expression of ligand-receptor pairs upon co-culture of tumor supportive fibroblasts with
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chemokines CCL-2, -7, -8 similar to that seen by co-culture with
breast cancer cells (Table 2). However, IL-1b did not induce
expression of WISP1, STC1, AREG, or NRG1. Interestingly, a
combination of IL-1b and AREG lead to significant upregulation of
WISP1 in addition to stimulation of CCL-2, -7, -8. In contrast,
none of the fibroblast factors were induced when TGF-b and IL-1b
were combined (Table 2). Based on these results, it seems likely
that the ability of breast cancer cells to induce the full spectrum of
pro-tumorigenic fibroblast-secreted proteins involves a multitude
of interacting factors, including some not previously identified. We
also found that co-culture of tumor-promoting fibroblasts with a
normal, non-malignant breast epithelial cell line, MCF10A, was
able to induce fibroblast expression of two out of the seven factors
induced by breast cancer cells, namely AREG andWISP2 (Table 2).
For these two factors, it would appear that breast epithelial cells per
se, regardless of tumorigenic properties, elicit the same response in
fibroblasts. This result is consistent with the key role that stromal
AREG plays in normal mammary development [37].
Discussion
Numerous studies have used the co-injection assay to identify
the factors produced by fibroblasts that are responsible for
promoting tumorigenicity. These studies have identified single
factors that when inhibited strongly suppress the ability of
activated fibroblasts to promote tumorigenicity, and they include
scatter factor, SDF-1, MMP14, NF-kB, osteopontin, TGF-b, and
CCL2 [12–17]. However, these studies did not address whether the
single factors were unique in their capacity of promoting
fibroblast-supported tumorigenicity, nor did they compare differ-
ent factors. Here, we used comparative genomics to identify 42
candidate mediators of fibroblast-promoted tumorigenicity and we
tested the functional impact of a set of five of these factors.
Surprisingly, we found that four of the five tested factors promoted
tumorigenicity, three of them strongly (CCL7, CCL2, and AREG)
and one of them weakly (CCL8) (Table 3). Although the fifth factor
STC1 significantly affected tumorigenicity by the area under the
tumor growth curve test (Table 3), it failed to show significant
effects using t-tests at any single time points (data not shown).
Since we only tested five of the 42 fibroblast-secreted-factors that
were induced by breast cancer cells, it seems highly likely that an
even greater number of fibroblast-secreted factors play a role in
promoting tumorigenicity. Thus, our study indicates that even in a
single system there are a large number of secreted factors involved
in the ability of fibroblasts to promote carcinomas, rather than a
single important mediator.
Intriguingly, our results also indicate widely diverse mechanisms
for fibroblast-secreted factors in the promotion of tumorigenicity.
The strong effects of fibroblast CCL7 appeared to be caused by a
significant effect on cancer cell proliferation (Table 3), which was
unique among the factors tested. We also found that reducing
cancer cell expression of the CCL7 receptor, CCR1, also reduced
fibroblast-induced proliferation. In contrast, the strong tumor
promoting effects of fibroblast CCL2 was associated with different
effects on the tumor microenvironment, as we found significant
decreases in both angiogenesis and recruitment of innate immune
cell upon silencing of CCL2. CCL8 had weaker effects on tumor
growth than the other tested chemokines, which likely reflects it
inability to affect either tumor proliferation or vascularity (Table 3).
Fibroblast AREG also had very strong effects on tumor growth,
and influenced both the total number of activated fibroblasts in the
tumors and the survival of the cancer cells, a combination not
basal breast cancer cells. The fold-change in ligand expression in tumor-supportive fibroblasts (x-axis) is plotted along with the fold-change in
receptor expression in breast cancer cells (y-axis). (B) Tumorigenicity of Cal51 cells expressing either control shRNA or shRNAs targeting CCR1 co-
injected with HFFF2 fibroblasts. Tumor take rate for each group is indicated. Asterisks indicate significant differences in tumor volumes for shCCR1-1
and shCCR1-2 co-injection groups compared to control (p,0.01) (C) Tumorigenicity of Cal51 and HFFF2 fibroblasts coinjected in the following
combinations: Cal51 cells expressing shRNAs targeting CCR1 co-injected with HFFF2 fibroblasts expressing control shRNA; Cal51 cells expressing
control shRNA coinjected with HFFF2 cells expressing shRNA targeting AREG; Cal51 cells expressing shRNAs targeting CCR1 co-injected with HFFF2
fibroblasts expressing shRNA targeting AREG. Tumor take rate for each group is indicated. Asterisks indicate significant differences (p,0.05). (D)
Histological and Immunohistochemical analysis of the effects of suppressing CCR1 in Cal51 cells and amphiregulin in tumor-supportive fibroblasts
HFFF2 as described in the legend to Figure 2 but also tumor necrosis which was evaluated on hematoxylin and eosin stained sections. Scale bars
represent 50 mm for Ki67 and 7/4, 100 mm for a-SMA and 500 mm for hematoxylin and eosin staining. (E) Quantification of microenvironment effects
as described in the legend to Figure 2. Five different fields of three different tumors per group were scored. Error bars represent SEM. Hashtag
indicates a significant difference in proliferation in the CCR1 silenced group compared to the control where p = 8.9E-04. Asterisk indicates a significant
difference in proliferation in the CCR1 and AREG silenced group compared to the control where p= 0.01. (F) Similarly performed quantification of
neutrophils and monocytes where Hashtag indicates a significant difference in the CCR1 silenced group compared to the control where p = 4.6E-04.
Asterisk indicates a significant difference in the CCR1 and AREG silenced group compared to the control where p = 2.4E-05. (G) Similarly performed
quantification of activated mesenchymal cells. Asterisk indicates a significant difference in the CCR1 and AREG silenced group compared to the
control where p = 0.003. (H) Similarly performed quantification of necrotic area. Asterisk indicates a significant difference in the CCR1 and AREG
silenced group compared to the control where p = 0.02.
doi:10.1371/journal.pgen.1003789.g007
Table 2. Induction in fibroblasts of chemokines and growth
factors after treatment with single or combination of factors.
Treatment Fold induction
CCL2 CCL7 CCL8 WISP1 STC1 AREG NRG1
AREG 1.0 1.3 0.7 1.6 0.9 1.0 1.1
IL1b 6.3* 6.3* 60.4* 1.0 1.7 1.1 1.3
TGFb 0.7 1.9 1.9 1.4 0.3 0.6 1.9
IL1b+AREG 10.1* 7.8* 55.3* 4.0* 2.0 1.4 1.4
IL1b+TGFb 1.3 2.5 0.9 1.9 0.4 0.6 2.0
TGFb+AREG 0.4 1.6 ND 1.9 0.2 0.7 1.9
AREG+IL1b+TGFb 1.0 2.0 0.3 1.3 0.4 0.9 2.1*
MCF10A co-culture 1 1.1 1.1 2.1* 0.9 6.1* 0.9
Cal51 co-culture 5.7* 4.8* 63.7* 2.2* 7.0* 9.7* 2.3*
MDAMB231 co-
culture
6.2* 4.0* 114.8* 3.6* 11.8* 23.5* 4.0*
Induction of chemokines (CCL2, CCL7 and CCL8) and growth factors (AREG,
NRG1,WISP1 and STC1) in HFFF2 fibroblasts co-cultured with breast cancer
cells or normal breast epithelial cells (co-culture Cal51; co-culture MDAMB231;
MCF10A co-culture) or upon treatment with individual factors IL1b (10 ng/ml),
AREG (100 ng/ml) or TGFb (10 ng/ml) or a combination was measured by qRT-
PCR. Fold induction was calculated as the change in gene expression
compared to untreated HFFF2 control cells. GAPDH was used as the
normalization control for all experiments. Data shown is average of three
experiments. Asterisk indicated that the fold induction is significant; p,0.05.
doi:10.1371/journal.pgen.1003789.t002
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observed with any other tested factor. Interestingly, secretion of
amphiregulin by fibroblasts appeared to potentially act as a
chemoattractant to recruit new fibroblasts and induce their
proliferation and activation, resulting in a tumor microenviron-
ment that is enriched in activated fibroblasts. Thus, in a single
system of carcinoma cells and tumor-supportive fibroblasts, several
factors play key roles.
Our study also sheds light on how cancer cells modify the stromal
cells to enable them to promote tumorigenicity. We tested several
cancer cell-secreted factors, previously reported to influence stromal
cells, but none of them were able to induce the full panel of verified
tumor-promoting fibroblast factors as well as the cancer cells
themselves. Even in one simple system, it appears that cancer cells
act on fibroblasts through multiple factors, resulting in the secretion
of another complex set of factors that influence cancer cells and
other components of the tumor microenvironment.
One of the key findings of our study was that inhibiting multiple
interactions between cancer cells and fibroblasts is more efficacious
than blocking individual pathways. This finding is not completely
unexpected in light of the complexity of the tumor microenviron-
ment and in fact previous reports have suggested this as a
possibility [20,41]. Nevertheless, this result highlight that the
different interactions are non-redundant and act in parallel, but it
also suggests that effective anti-stromal fibroblast therapeutic
strategies can be achieved by taking a multi-targeted approach.
Future research towards this end will need to employ models that
closely resemble the type of tumors to be targeted in human
patients. This presents many challenges, including the ability to
selectively target endogenous fibroblasts in tumor tissues, along
with the ability to monitor the in vivo response of tumor-associated
fibroblasts. Despite these challenges, our study shows that there




All genomic data for this study, including expression analysis of
both fibroblasts and breast cancer cells, have been deposited in the
Gene Expression Omnibus (GEO) repository (GSE41678). http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=bnepxkssyoamgdu
&acc=GSE41678
Cell lines, co-culture, flow cytometry and gene
expression analysis
Breast cancer cell lines and human fibroblast strains were
obtained from ATCC (Manassas, VA), DSMZ (Braunschweig,
Germany) or Sigma (St.Louis, MO) and grown under standard
tissue culture conditions in growth medium recommended by the
supplier. For dual-color co-culture experiments, breast cancer cells
stably expressing Discosoma sp. red fluorescent protein (DsRed) and
human fibroblasts stably expressing Zoanthus sp. green fluorescent
protein (ZsGreen) were generated using pRetroX-IRES-DsRe-
dExpress vector and pRetroX-IRES-ZsGreen1 vector (Clontech,
CA) respectively via retroviral transduction (detailed description in
Supplemental Experimental Procedures). None of the experiments
utilized multiple retroviral transfections. For the co-culture
experiments, we transfected the original fibroblasts with a
fluorescent marker in order to facilitate cell separation before
transcriptome analysis (the breast cancer cells were transfected
with a different fluorescent marker). For the shRNA experiments,
we transfected the original fibroblasts with validated shRNA
constructs from the Broad library. Co-culture of fluorescently-
tagged breast cancer cells and fibroblasts was initiated by plating
1.5 million fibroblasts into 10 cm dishes, and after 18 hours 1
million breast cancer cells were added and then incubated for six
days. Monocultures were performed in parallel for the same
Table 3. Comparison of the effects on tumorigenicity and the microenvironment of inhibiting different fibroblast-secreted factors.
Cal51+shHFFF2 Control shAREG shCCL2 shCCL8 shCCL7 shSTC1
Area under curve
Mean 1 0.37 0.27 0.58 0.26 0.60
SEM 0.01 0.03 0.02 0.02 0.03 0.03
pval ,0.01 ,0.01 ,0.01 ,0.01 0.01
Endpoint tumor volume
Mean 1 0.41 0.43 0.71 0.34 0.89
SEM 0.01 0.02 0.03 0.03 0.03 0.04
p value ,0.01 ,0.01 0.04 ,0.01 0.46
Tumor microenvironment
Proliferation 1 0.91 0.95 0.93 0.58 NA
p value 0.06 0.35 0.43 ,0.01
Immune cells 1 0.81 0.33 0.52 1.11 NA
p value 0.14 ,0.01 ,0.01 0.34
Blood vessels 1 0.88 0.44 1 0.85 NA
p value 0.24 ,0.01 0.98 0.11
Mesenchymal cells 1 0.17 0.77 0.63 0.78 NA
p value ,0.01 0.08 0.051 0.11
Summary of results obtained from tumorigenicity assays and immunohistochemical characterization of the tumor microenvironment in AREG, CCL2, CCL7, CCL8 and
STC1 silenced tumors compared to non-target control. Three major parameters, namely total area under the curve (AUC), endpoint tumor volume (week 6 post
injection) and immunohistochemistry of tumor microenvironment were used to quantify differences between the control and experimental groups.
doi:10.1371/journal.pgen.1003789.t003
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duration. Following co-culture or mono-culture, cells were
trypsinized and resuspended in FACS sorting buffer (PBS+1%
FBS) for separation into DsRed+ and ZsGreen+ populations using
an ARIA II flow cytometer and analyzed using FACS DiVA
software (Becton Dickenson, CA). Total RNA was isolated using
RNeasy kit (Qiagen, Netherlands) and hybridized to Gene 1.0 ST
arrays (Affymetrix, CA). Data was extracted, background correct-
ed, normalized, and converted from probe values to gene values
using the AROMA R package (www.aroma-project.org).
Tumorigenicity assays
All studies utilizing human xenograft experiments were
approved by and in accordance with Cold Spring Harbor
Laboratory’s Institutional Animal Care and Use Committee. Five
to six week old female nude mice (NCR nu/nu; Charles River
Inc., Wilmington, MA) were irradiated at 400 cGy 24–36 hours
prior to injections. One million breast cancer cells were
trypsinized, resuspended with or without 1.5 million fibroblasts
in 100 ml DMEM and injected subcutaneously into both flanks of
irradiated, nude mice. Growth was followed over time by taking
caliper measurements at indicated time points. Tumor volume was
measured as 0.526length6width2. Tumors were excised six-eight
weeks post injections or when one of the measurements reached
2 cm.
Immunostaining and quantification
Immunostaining procedure is described in detail in Supple-
mentary Experimental Procedures. The primary antibodies used
for immunostaining are as follows: a-SMA (1:2000; # 1A4;
Sigma-Aldrich), CD31 (1:100; ab28364; Abcam), antigen 7/4
(1:400, CL8993AP, Cedarlane), Ki-67 (1:2000; MIB5; Dako),
pEGFR (1:100; 1138-1; Epitomics) and GFP (1:1000; ab290;
Abcam). Immunostained slides were quantified by counting (for 7/
4, Ki-67 and CD31), by percentage of stained area (for a –SMA
and pEGFR) using Image J software (NIH, Bethesda, MD).
Additional methods are found in the file Text S1.
Supporting Information
Figure S1 Identification of tumor-supportive fibroblasts for
basal breast cancer cells. (A–D) The effect of four different
human fibroblast lines on the ability of the basal breast cancer
cell line Cal51 to form tumors in nude mice. From left to right,
the tumorigenic effects of co-injection of fibroblasts HFFF2 or
HFF1, followed by the effects of co-injecting fibroblasts
CCD1112Sk and Wi-38. Asterisks mark groups that are
significantly different, p,0.05, n.10 per group. Data are
expressed as the mean 6 SEM. (E–H) Identifiably performed
experiments with another basal breast cancer cell line, MDA-
MB-231.
(EPS)
Figure S2 Time course study of the presence of co-injected
HFFF2 fibroblasts in tumors formed with Cal51 cells. (A) The
presence of GFP tagged human HFFF2 fibroblasts at different
times after co-injection with Cal51 cancer cells. Activated
fibroblasts were visualized with a red fluorescently labeled
antibody to a-SMA and tissue counterstained with DAPI. Scale
bars represent 100 mm. (B) the presence of HFFF2 fibroblasts is
more easily visualized without labeling for a-SMA.
(TIF)
Figure S3 Quantitative RT-PCR validation of selective induc-
tion in tumor-supportive fibroblasts of candidate stromal media-
tors upon co-culture of basal carcinoma cells. (A) Quantitative RT-
PCR validation of the selective up regulation AREG upon co-
culture with tumor-supportive fibroblasts (HFF1 and HFFF2)
versus tumor-neutral fibroblasts (Wi-38 and CD1112SK). ‘‘+’’
indicates co-culture with the indicated breast cancer cell line. Data
are expressed as the mean 6 SEM. (B) As in (A) but measuring
CCL2. (C) As in (A) but measuring CCL7. (D) As in (A) but
measuring CCL8. (E) As in (A) but measuring STC1.
(EPS)
Figure S4 Effects of shRNA silencing of CCL2, CCL7 or CCL8
on the tumor-supportive function of co-injected fibroblasts. (A)
Quantitative RT-PCR validation of shRNA suppression of
CCL7 in HFFF2 fibroblasts. Asterisk indicates significant
differences between expression of CCL7 between the control
(shN.T.) and the knockdown groups (p,0.05). Error bars
represent SEM. No significant difference was observed in the
expression of CCL7 between the two knockdown groups
(p = 0.21). (B) The effects of shRNA suppression of CCL2 on
the viability of HFFF2 fibroblasts were determined using an
MTT assay 48 hours post plating. No significant effects were
observed. n = 6; Error bars represent SEM. (C) As in (B) but
testing the effects of CCL7 suppression. (D) As in (B) but testing
the effects of CCL8.
(EPS)
Figure S5 Validation of shRNAs targeting AREG and effects of
amphiregulin on tumor-cell proliferation. (A) AREG expression in
HFFF2 fibroblasts expressing either control or shRNAs targeting
AREG. GAPDH expression was used as a reference. Asterisk
indicates a significant difference in AREG expression between
control and shAREG-1, 2 and 3 (p = 0.016, 0.014 and 0.02
respectively). Data are expressed as the mean 6 SEM. (B)
Relative viability of HFFF2 fibroblasts expressing control or
shRNAs targeting AREG as assayed by MTT following 48 hours
of culture. Data are expressed as the mean 6 SEM. (C)
Proliferation of breast cancer cells (Cal51; gray bars or MDA-
MB-231; red bars) was assayed by MTT following 72 hours of
culture with the indicated amounts of amphiregulin. Data are
expressed as mean 6 SEM.
(EPS)
Figure S6 Combined shRNA suppression of CCR1 and AREG
blocks tumor-supportive function of co-injected fibroblasts. (A)
Quantitative RT-PCR validation of shRNA suppression of CCR1
in Cal51 breast cancer cells as well as demonstration that
shRNAs targeting CCR1 suppress protein levels in Cal51 cells. (B)
The effects of shRNA suppression of CCR1 on the viability of
Cal51 cells was determined using an MTT assay 48 hours post
plating. (C) Tumorigenicity of Cal51 cells expressing either
control shRNA or shRNAs targeting CCR1. Tumor take rate for
each group is indicated. No significant differences were observed
between the groups. Errors represent SEM. (D) Immunohisto-
chemical analysis of the tumor microenvironmental effects of
suppressing tumor cell CCR1 on blood vessel recruitment. Cal51
cells expressing control shRNA or shRNA targeting CCR1 were
coinjected with HFFF2 fibroblasts expressing control shRNA or
Cal51 expressing shRNA to CCR1 were injected with HFFF2
fibroblasts expressing shRNA to AREG. Scale bars represent
50 mm. (E) Quantification of blood vessel recruitment in tumor
groups presented in (D). No significant difference was observed
between the groups.
(TIF)
Table S1 Significantly activated pathways in the three tumor-
stromal datasets.
(XLS)
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Table S2 320 genes that were more than 2-fold greater induced
in tumor-promoting fibroblasts.
(XLSX)
Text S1 Supplemental methods.
(DOCX)
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